Adults 18 to 60, any sex, with Opioid-use Disorder. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Patients Who Receive the Second Injection of XR-NTX.Primary· 4 weeks after 1st injection
Percentage of patient who initiated Procedure 1 and completed the study receiving the 2nd injection of XR-NTX
Group
Value
95% CI
Procedure 1
6
Sponsor's own description
The study will enroll 30 opioid-dependent participants into an open-label pilot outpatient study of methods to facilitate induction and stabilization onto XR-NTX. There will be three different methods of XR-NTX induction using increasing doses of oral naltrexone and buprenophine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
NCT06379984 — Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use
· Phase 2
· recruiting
NCT06316830 — Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
· Phase 2, PHASE3
· recruiting
NCT06086275 — Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder
· Phase 1
· completed
NCT06406400 — Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics o
· Phase 1
· terminated
NCT06008990 — Maternal Brain Imaging in Opioid Use Disorder
· active not recruiting
Other recruiting trials for Opioid-use Disorder
Currently open trials in the same condition.
NCT04783558 — Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk
· NA
· active not recruiting
NCT05011266 — Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
· Phase 2, PHASE3
· recruiting
NCT05039554 — Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment
· NA
· recruiting
NCT04738825 — Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With Pr
· NA
· recruiting
Other New York State Psychiatric Institute trials
Trials by the same sponsor.
NCT05416658 — Shared Decision Making for Antipsychotic Medications
· NA
· not yet recruiting
NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
· Phase 1, PHASE2
· not yet recruiting
NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual
· Phase 2
· not yet recruiting
NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD
· Phase 2
· suspended
NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis
· Phase 1
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
Last refreshed: 2 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03113409.